We reasoned that since the conformation of ER bound to Tam differs from that of E2-bound ER [14], a screening of compounds based on the Tam-bound ER might identify compounds whose binding to ER would synergize with Tam and help re-sensitize resistant breast cancers to Tam. The gene discussed is STIM1; the disease is breast carcinoma.